Dingell to Companies…Stop Using “Misleading and Deceptive” Ads

Posted by Joe Arite on May 22nd, 2008
Tags: Congress, DTC, FDA, Johnson and Johnson, Procrit

House Energy and Commerce Committee Chair, John Dingell (D-MI) and Oversight Subcommittee Chair, Bart Stupak (D-MI) sent letters to Johnson & Johnson, Merck, Schering-Plough and Pfizer asking them to stop using “misleading and deceptive” direct-to-consumer advertising.

Dingell in a statement said, “Marketing department leaders have failed to commit to reducing misleading and deceptive ads, so we’re now asking the CEOs to make this agreement.” Stupak said, “We intend to make certain that drug companies market their product properly in order to protect American consumers from manipulative commercials designed to mislead and deceive for profit.”


The letters relate to a May 8 hearing in which representatives from the four pharmaceutical companies defended their DTC advertising. The hearing focused on three broadcast ads: Pfizer’s ads for Lipitor featuring Dr. Robert Jarvik, Merck/Schering-Plough’s “Food & Family” ads for Vytorin and Johnson & Johnson’s ads for Procrit.

The letters ask for an “immediate” response, while a second hearing on DTC advertising is being considered.

Click here to read the Energy and Commerce Press Release.

Leave a Comment Comments RSS

Your comments are welcome. However, specific medical advice will not be provided, and we urge you to consult with a qualified physician for diagnosis and for answers to your personal questions.

C3 is not responsible for the medical accuracy of any comments left by persons other than C3 staff members. C3 staff members monitor comments and may respond where appropriate.

For the best response to your colorectal cancer treatment questions, please call our Answer Line at 1-877-4CRC-111 (1-877-427-2111).

Search C3

Sign Our Petition

Guarantee access to colorectal cancer screening for all Americans who need it.

Get Involved

Subscribe to the C3 website

Get C3 news & updates

Get the latest articles in your email inbox or news reader as soon as they are published.

Subscribe